44.03MMarket Cap-645P/E (TTM)
1.080High1.040Low44.65KVolume1.080Open1.070Pre Close47.21KTurnover0.21%Turnover RatioLossP/E (Static)41.09MShares1.76052wk High0.43P/B22.32MFloat Cap0.63052wk Low--Dividend TTM20.83MShs Float18.948Historical High--Div YieldTTM3.74%Amplitude0.630Historical Low1.057Avg Price1Lot Size
Achilles Therapeutics Stock Forum
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
Achilles Therapeutics has received approval to transfer its listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective November 19, 2024. This transfer follows a May 17, 2024 notification from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per ADS. The company's ADSs will continue trading under the symbol ACHL. The transfer provides...
Achilles Therapeutics Discontinued Its TIL-Based CNeT Program And Closed Phase 1/2A CHIRON and THETIS Trials, And It Will Refocus Its Strategy To Explore Further Engagement With Third Parties, The Company Has Engaged BofA Securities To Provide Strategic Financial Advice
NEWS
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Moomoo 24/7· 1 min ago
Achilles Therapeutics (ACHL.Improved VELOS manufacturing process delivering higher cNeT doses.
Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024.
First three patients dosed in CHIRON and T...
Watchlist.
$ZyVersa Therapeutics (ZVSA.US)$ $Roma Green Finance (ROMA.US)$ $Veru Inc (VERU.US)$ $Achilles Therapeutics (ACHL.US)$ $Gaxos.ai (GXAI.US)$ $Applied Therapeutics (APLT.US)$ $Sonder Holdings (SOND.US)$
📊⚡️📊
No comment yet